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Introduction {#sec004}
============

Reduced levels of C1 esterase inhibitor (C1-INH) may be due to genetic defects in the SERPING1 gene (hereditary angioedema---HAE) or acquired deficiency (acquired angioedema---AAE) often associated with lymphoproliferative disorders. In most AAE patients, neutralizing anti-C1-INH antibodies are present \[[@pone.0230128.ref001],[@pone.0230128.ref002]\]. Uncontrolled contact/kinin-systems due to C1-INH deficiency generate bradykinin, the mediator of increased vascular permeability, resulting in recurrent angioedema attacks that may affect the extremities, genitourinary tract, face, oropharynx, larynx, and abdomen \[[@pone.0230128.ref001],[@pone.0230128.ref003]\].

In patients with C1-INH deficiency, dental procedures are potential triggers of angioedema attacks that may even affect the larynx \[[@pone.0230128.ref004]\], endangering the patient's life \[[@pone.0230128.ref005]\]. Since angioedema with C1-inhibitor deficiency is a rare disease, dentists are often unfamiliar with the management of attacks and do not dare to treat dental diseases in these patients. Similarly, patients are reluctant to undergo dental care because of the fear of potential attacks. As a consequence, these patients may suffer a lack of proper dental care.

The referral center for hereditary angioedema in Milano collaborates with the dentistry outpatient department to guarantee that patients affected by angioedema due to C1-INH deficiency receive proper dental care.

The aim of this study was to assess:

1.  the hurdles in receiving dental care;

2.  the effectiveness of short-term prophylaxis (STP) in preventing angioedema attacks;

3.  the positive impact of dental care on the disease in patients with angioedema.

The latter analysis was performed in order to test the hypothesis that proper dental treatment results in an improvement in the course of the disease.

Methods {#sec005}
=======

Ethics statements {#sec006}
-----------------

The study was approved by the Comitato Etico Interaziendale Milano Area A with protocol number 2015/SP/253. Data collection and analysis were conducted by the patients' own physicians; therefore, patient confidentiality was well maintained. The study was conducted in accordance with the principles of the Declaration of Helsinki.

Written informed consent for using their data for this study was collected by the patients, or, if under age, their parents or legal guardians.

Study population {#sec007}
----------------

The medical records of all patients affected by angioedema due to C1-INH who were diagnosed according to the criteria outlined by the Hereditary Angioedema International Working Group \[[@pone.0230128.ref001]\] and treated in the dentistry outpatient department of ASST Fatebenefratelli Sacco hospital (Milan, Italy) from 2009 to 2017 were considered for the analysis (see also [S1 Data](#pone.0230128.s001){ref-type="supplementary-material"}).

The following data were collected from patients' records: demographic information, hurdles in access to dental care, oral health at first visit, follow-up, dental procedures, type of angioedema, attack frequency, attack therapy, long- and short-term prophylaxis, and onset of attacks in the 48 hours after the procedure. Data on attack frequency were collected from angioedema records one year before and one year after the procedure. Missing data in records were collected by phone calls with patients.

In almost all patients STP consisted of the administration of plasma-derived C1-INH (pd C1-INH, Berinert^®^, CSL Behring, Pennsylvania, USA) one to three hours before the procedure. In one patient attenuated androgens (danazol 400mg/day) were administered every day starting five days before the procedure, and continued for two days after. In HAE and AAE patients, 1,000 IU and 1,500 IU were given, respectively.

Endpoints {#sec008}
---------

The primary endpoints were:

1.  percentage of patients encountering hurdles in the access to dental care;

2.  percentage of procedures followed by post-procedural attacks in patients receiving and nonreceiving a prophylaxis for angioedema

The secondary endpoint was the number of attacks per month in the 12 months following the procedure compared with the frequency in the year preceding the procedure.

Severity of oral and angioedema disease {#sec009}
---------------------------------------

To evaluate the severity of oral pathology in our patient population, we established a score based on the evaluation of plaque, gingivitis, periodontal disease, caries, abscesses, need for tooth extractions, edentulism, odontogenic cysts, and need for implantation ([Table 1](#pone.0230128.t001){ref-type="table"}).

10.1371/journal.pone.0230128.t001

###### Score to categorize the severity of oral pathology: Absent if the sum of points equals 0, mild if it is between 1 and 3, moderate 4--6, severe ≥7.

![](pone.0230128.t001){#pone.0230128.t001g}

  Pathology                     Presence/number   Points
  ----------------------------- ----------------- --------
  Plaque                        No                0
  Yes                           1                 
  Gingivitis                    No                0
  Yes                           1                 
  Gingival pockets or diffuse   2                 
  Periodontal disease           No                0
  Yes                           2                 
  Caries                        0                 0
  1--4                          1                 
  \>5                           2                 
  Abscesses                     No                0
  Yes                           2                 
  Need for tooth extractions    0                 0
  1--3                          2                 
  \>4                           3                 
  Edentulism                    0                 0
  Partial                       3                 
  Total                         5                 
  Odontogenic cysts             No                0
  Yes                           2                 
  Need for implantation         No                0
  Yes                           2                 

The dental procedures performed were oral hygiene, dental fillings and root canal treatment, extractions, devitalizations, abscess care, dental prostheses, dental bridges, dental implants, treatment of odontogenic cysts, and laser excision of tongue tumors.

The severity of the course of angioedema was evaluated considering the number of attacks per month before and after dental procedures ([Table 2](#pone.0230128.t002){ref-type="table"}).

10.1371/journal.pone.0230128.t002

###### Score to categorize the severity of angioedema course based on the number of attacks per month.

![](pone.0230128.t002){#pone.0230128.t002g}

  N. of attacks/month   Points
  --------------------- --------
  \< 1                  1
  1                     2
  2                     3
  3                     4
  ≥ 4                   5

Statistical analyses {#sec010}
--------------------

Continuous variables were reported as median and interquartile range (IQR). Categorical variables were reported as absolute frequencies and percentages. These calculations were performed by means of MS Excel 2010^®^.

Results {#sec011}
=======

Twenty-nine patients with angioedema due to C1-INH deficiency were visited in the dentistry department of ASST Fatebenefratelli Sacco hospital in the period considered. Fourteen were male (48.3%). The median age was 45 years (IQR = 24--53). The youngest patient was 8 years old, while the eldest was 85 years old. Twenty-seven of them were affected by C1-INH-HAE (93.1%) and two by C1-INH-AAE (6.9%).

According with records, 17/27 patients (63.0%) encountered hurdles in accessing dental care (data about two patients were missing). Two patients, 13- and 19-year-olds, were teenagers and their oral status at the first visit was judged not pathological. Among patients with pathological oral status, the majority (59.26%) had moderate-to-severe oral disease ([Table 3](#pone.0230128.t003){ref-type="table"}).

10.1371/journal.pone.0230128.t003

###### Oral pathological status of patients (n = 27) at the first visit, based on our severity score.

![](pone.0230128.t003){#pone.0230128.t003g}

  Pathological oral status   Score        Patients per score (n, %)   Total patients (n, %)
  -------------------------- ------------ --------------------------- -----------------------
  Mild                       1            3 (11.11%)                  11 (40.74%)
  2                          3 (11.11%)                               
  3                          5 (18.52%)                               
  Moderate                   4            7 (25.92%)                  9 (33.33%)
  5                          1 (3.70%)                                
  6                          1 (3.70%)                                
  Severe                     7            4 (14.81%)                  7 (25.92%)
  8                          3 (11.11%)                               

Median score was 4 (IQR = 2--6).

The most common conditions were caries (48.4% of patients), need for tooth extractions (41.9%), and edentulism (38.7%).

Nine out of twenty-nine patients had a first visit and did not undergo dental procedures in our dentistry department: two had a non-pathological status and seven had mild-to-moderate oral status, and after the first visit have turned to other dentistry services so were not considered for follow-up.

In addition, we looked for a correlation between patient age and the disease pattern, and we found that patients affected by more severe oral pathology tended to be elder, without statistical significance (p = 0.1953) ([Fig 1](#pone.0230128.g001){ref-type="fig"}).

![Boxplot showing age distribution according to oral disease severity.\
The bold lines represent the median values, the boxes indicate the interquartile range, and the whiskers represent the minimum and maximum values. Please, refer to [Table 1](#pone.0230128.t001){ref-type="table"} for the score used to categorize the severity of oral pathology.](pone.0230128.g001){#pone.0230128.g001}

Conversely, no correlations were found between age and angioedema severity.

Therefore, 20 patients (69.0%) were considered for further analyses. In this group of patients, eight were male (40.0%). The median age was 45 years (IQR = 27--61). The age range was 8--89 years, but the only underage patient (the 8-year-old one) underwent a single procedure, that was an oral hygiene. Eighteen patients (90.0%) were affected by C1-INH-HAE and two (10.0%) by C1-INH-AAE.

Overall, ten patients (50%), affected by C1-INH-HAE, were on LTP: nine with attenuated androgens and one with pdC1-INH administered intravenously. Both the patients with C1-INH-AAE were not on LTP.

Seventy-five procedures were performed on twenty patients ([Table 4](#pone.0230128.t004){ref-type="table"}).

10.1371/journal.pone.0230128.t004

###### Type of procedures and of prophylaxis undertaken (n = 20).

![](pone.0230128.t004){#pone.0230128.t004g}

  Type of procedure                           Total (n.)   STP only (n.)   LTP only (n.)   STP and LTP (n.)   No STP, no LTP (n.)
  ------------------------------------------- ------------ --------------- --------------- ------------------ ---------------------
  Dental fillings and root canal treatments   33           14              6               13                 0
  Extractions                                 20           7               1               11                 1
  Oral hygiene                                10           4               4               1                  1
  Dental prostheses                           4            0               0               4                  0
  Dental implants                             2            0               0               2                  0
  Dental bridges                              2            0               2               0                  0
  Abscess care                                1            0               0               1                  0
  Devitalizations                             1            0               0               1                  0
  Treatment of odontogenic cysts              1            1               0               0                  0
  Laser excision of tongue tumors             1            1               0               0                  0

LTP, long-term prophylaxis; STP, short-term prophylaxis.

[Table 4](#pone.0230128.t004){ref-type="table"} shows types of procedure and the preceding prophylaxis.

The majority of procedures were undertaken after prophylaxis. In particular, 60 procedures (80%) were preceded by STP in patients with/without LTP. Thirteen procedures were undertaken without STP in patients regularly taking LTP.

Only two procedures in two hereditary angioedema patients were not preceded by any type of prophylaxis: one was oral hygiene, while the other was performed on a patient who had an angioedema attack within 48 hours of the dental extraction.

An attack after the extraction of one tooth occurred in an AAE patient not in LTP who took pdC1-INH as STP.

Data about the frequency of attacks were available in 19/20 patients.

In four patients the frequency of attacks per month in the year after the procedure was reduced compared to the frequency of attacks per month in the year before; in all other patients it remained unchanged. None experienced an increase in the number of attacks after the procedures ([Fig 2](#pone.0230128.g002){ref-type="fig"}).

![Angioedema severity before and after dental procedures (refer to our score in [Table 2](#pone.0230128.t002){ref-type="table"}).](pone.0230128.g002){#pone.0230128.g002}

Discussion {#sec012}
==========

In this study, the majority of patients with angioedema (63.0%) reported that they had encountered hurdles in accessing dental care. Often dentists are not aware of this disease and of the correct management of patients with angioedema undergoing dental procedures. Due to the risk of post-procedural attacks, dentists dare not treat these patients. As suggested by Forrest and colleagues \[[@pone.0230128.ref005]\], dental practitioners should be informed about this pathology, even if rare, and should add a specific question about previous swelling episodes in their habitual questionnaire for anamnestic purpose.

Difficulties in accessing dental care can result in a poor oral condition. In particular, 59.25% of patients recruited in this study had a moderate-to-high score for the severity of oral pathology. It is well known that infections may trigger angioedema attacks \[[@pone.0230128.ref006],[@pone.0230128.ref007]\]. An observational study carried out by the group of Farkas \[[@pone.0230128.ref008]\] investigated the trigger factors in 27 patients affected by C1-INH-HAE. Patients recorded the occurrence of potential trigger factors every day for 7 months, whether or not they experienced an attack. The likelihood of angioedema attack associated with infection was 38%.

Other studies demonstrated that the eradication of *Helicobacter pilori* infection in C1-INH-HAE patients was effective in reducing the frequency of attacks \[[@pone.0230128.ref009],[@pone.0230128.ref010]\].

Since the need for dental procedures is indicative of infections localized in the oral cavity, improving dental care may be a useful strategy to reduce the frequency of angioedema attacks \[[@pone.0230128.ref011]\]. In this study, treating C1-INH-HAE patients with severe oral pathology had a positive impact on the course of the disease: in 20% of patients the frequency of attacks was reduced after dental care. We eliminated a possible trigger of angioedema attack, but, as it is not possible to eradicate the underlying pathology, we did not expect an improvement in all the patients. Among those who improved, one had mild, two had moderate, and one had severe oral pathology. The average oral pathology score was slightly worse in this subpopulation compared with the other patients (4.75 vs 4). This finding indicates that the subpopulation who benefits most from dental procedures has more severe oral pathology.

As stated by Longhurst \[[@pone.0230128.ref012]\] and the Italian guidelines on the diagnostic and therapeutic management of C1-INH-HAE \[[@pone.0230128.ref013]\], STP should be considered in these patients before dental procedures. Most evidence is available for pdC1-INH as STP. Danazol, in case no other drugs are available, may be used.

STP was effective in preventing post-procedural attacks. All C1-INH-HAE patients with STP, in the presence or in the absence of LTP, did not suffer attacks. Further confirmation comes from the fact that one patient had an attack just when not protected by STP.

In fact, a patient with C1-INH-HAE without LTP, informed of the risk of the possible attack, decided not to be treated with STP before a tooth extraction. This patient had a post-procedural attack, located in the oropharynx, that was treated in the Emergency Department (ED) with pdC1-INH, with symptoms resolution. When this patient underwent another procedure (tooth extraction), he did not manifest any attack after receiving STP with pdC1-INH.

The effectiveness of STP with pdC1-INH was shown by the retrospective study of Bork \[[@pone.0230128.ref004]\], which analyzed clinical records of C1-INH-HAE patients undergoing tooth extractions. Angioedema attacks occurred in 21.5% (124/577) of tooth extractions without STP versus 12.5% (16/128) of tooth extractions with STP, highlighting a 41.9% reduction in angioedema attacks when using pdC1-INH before the procedure (p \< 0.05).

In the analysis of Bork, many attacks occurred within 12 hours after tooth extractions, making the night following the dental procedure the most dangerous moment for attack onset. Finally, the retrospective analysis of Bork detected a significant dose-response effect (21.5% attacks without prophylaxis, 16.0% with 500 IU, and 7.5% with 1,000 IU). A trend toward a dose-response effect of pdC1-INH is also suggested by Magerl and coauthors in the analysis of Berinert Registry, collecting data from 30 US and 7 European centers between 2010 and 2014 \[[@pone.0230128.ref014]\].

In our cohort of C1-INH-HAE patients, pdC1-INH (Berinert^®^) was used as STP at a fixed dose of 1,000 IU.

Another retrospective analysis \[[@pone.0230128.ref006]\] confirmed the effectiveness of pdC1-INH as STP, highlighting also a superiority if compared with danazol and tranexamic acid. Invasive medical interventions, including dental procedures, before and after the diagnosis of C1-INH-HAE were analyzed in order to compare the onset of attacks with and without STP. The analysis detected a significant reduction in the number of edematous episodes when using a STP (39/89 vs 3/55, i.e. 43.8% vs 5.4%). In our cohort, only one patient received danazol as STP, thus a comparison with STP with pdC1-INH is not possible.

In our study, in C1-INH-AAE patients higher doses of pdC1-INH were used for STP, since it is known that in these patients the catabolism of C1-INH is faster \[[@pone.0230128.ref002]\].

One patient affected by C1-INH-AAE without anti-C1-INH antibodies underwent five dental fillings and root canal treatments, two oral hygiene procedures, and one laser excision of two tongue tumors with STP, and had no attacks.

Another patient affected by C1-INH-AAE with anti-C1-INH antibodies underwent a tooth extraction and manifested a post-procedural attack within 24 hours of the dental procedure despite STP (pdC1-INH). The patient was not on LTP. The attack, located in the oropharyngeal tract, was severe and treated in ED.

STP with pdC1-INH seems to be less efficacious in patients affected by AAE with anti-C1-INH antibodies. There is no evidence from randomized clinical trials that antifibrinolytic agents are effective for STP in patients with C1-INH-AAE. In addition, antifibrinolytic agents are contraindicated in some categories of patients, such as those receiving antiplatelet or anticoagulant therapy and those with procoagulant condition, such as the patient with AAE with anti-C1-INH antibodies enrolled in our study. For this reason, we used STP with pdC1-INH at higher doses in this patient.

In our study, the triggering procedure for angioedema attacks was tooth extraction. Bork and colleagues also reported that tooth extraction was the most common triggering factor in the head region in C1-INH-HAE patients \[[@pone.0230128.ref004]\]. Although dentists consider a tooth extraction in general population as a routine procedure, in patients with C1-INH deficiency it is a common trigger for an attack. Therefore, STP is strongly recommended in these patients who are undergoing tooth extraction.

This study has some limitations. First, the sample size is low, but the rarity of the disease makes it difficult to study a higher number of patients. An international register for C1-INH-HAE collecting data from high number of patients may overcome these issues. Such a register will allow physicians to better evaluate the effectiveness of the drugs used in this pathology, even for STP.

Second, the score used to evaluate the severity of oral disease in this study was developed by the authors since in the literature there is no consensus on this topic. Therefore, data concerning oral severity assessed at the first visit of this study cannot be compared with those found in the literature.

Third, the data collection of the study was carried out through information present in the patients' records. As well known, secondary data are less affordable than data coming from randomized clinical trials. Further interventional studies, even though difficult to perform owing to the rarity of the disease, are needed in order to confirm these conclusions.

Fourth, pediatric and adult patients were considered together. However, among those who underwent dental procedures, only one patient was underage and received just an oral hygiene.

Conclusions {#sec013}
===========

In conclusion, this analysis revealed that most patients with angioedema due to C1-INH deficiency encountered hurdles in receiving dental care because dentists are not familiar with this disease and its treatments.

STP with pdC1-INH was effective in preventing post-procedural attacks. However, rescue therapy should always be available for patients undergoing dental procedures.

A considerable percentage of patients (21.05%) experienced a reduction in the frequency of angioedema attacks after receiving dental care. This highlights the importance of treating oral pathologies in patients affected by angioedema due to C1-INH deficiency.

Taking into account our results and other data in the literature, we recommend considering tooth extractions as posing a high risk of attack in these patients and therefore advise the use of STP before these procedures.

Supporting information {#sec014}
======================
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REVIEWER

Reviewer \#1: I think this paper can only be accepted if the author\'s add and answer the following points in the current submission. It needs more statistical analysis to be done with statistical software packeges.

1\. Kindly add co-relation of patient age with the disease pattern. In current article patients age 8-85 years are added, which is a wide range.

2\. Add some more statistical data analysis as well as some statistical graph in this article.

AUTHORS

As required by Reviewer \#1, we performed more statistical analyses. We investigated the possible correlation between age and oral disease severity and between age and angioedema severity. We added two paragraphs and one figure in the Results section.

REVIEWER

3\. Add some more discussion to correlate the immunological effect of the disease process as well as therapeutic approach.

4\. Kindly add some more current relevant references.

AUTHORS

We added a more thorough explanation about the relationship between infections and occurrence of angioedema attacks in the Discussion section and we circumstantiated these data with appropriate bibliographic references.

REVIEWER

5\. Add some pictures to show the Angioderama and clarify the scoring process with more supporting images in the current population of the patient.

AUTHORS

We showed our scoring systems, adding Table 1 and Table 2 in the Methods section (see "Severity of oral and angioedema disease" paragraph).

REVIEWER

Reviewer \#2: The authors present data from a study on the management of dental procedures in patients with HAE or AAE due to C1-Inhibitor deficiency. It is adequately written and the conclusions presented are appropriately supported by the data. Although most of the conclusions reached by the authors are not novel, they do provide experimental support to previously reported observations with important implications for the management of these patients. Because of dealing with a rare pathology, the relatively small number of individuals recruited for this study is not to be considered a substantial limitation in its design.

AUTHORS

We thank the Reviewer for appreciating this work.

REVIEWER

Minor points:

\- Lines 175-176: The manuscript states that "....Most patients recruited in this study had a moderate-to-high score for the severity of oral pathology". However, according to Table 1, most of the patients studied (20/27) had a Mild to Moderate phenotype.

AUTHORS

The intended meaning was that the sum of patients with moderate and severe oral pathology is greater than 50%. In order to avoid misunderstandings, we changed the sentence indicating the precise percentage (59.25%).

REVIEWER

\- Lines 179-180: The amelioration of the patients' HAE course after dental care is a reasonable conclusion. Though, significant improvement of HAE was observed in as little as 20% of the studied cases. Wouldn't it be expectable to find a general improvement in the cohort after dental management? Were these 4 patients showing amelioration of HAE those exhibiting worse oral pathological scores?; that is, is there any correlation between the oral disease score and the beneficial effect of dental care on HAE?

Can the authors speculate in the discussion section on the hypothetical causes of the lack of response in an 80% of cases?

AUTHORS

We thank the Reviewer, as our manuscript would certainly benefit from further deepening of this topic.

We eliminated a possible trigger of angioedema attack, but, as it not possible to eradicate the underlying pathology, we did not expect an improvement in all the patients. No one worsened and 4 improved: we added in the Discussion section a thorough analysis of the severity of oral pathology.

The average oral pathology score was slightly worse in the subpopulation who experienced an amelioration compared with the other patients (4.75 vs 4). This finding indicates that the subpopulation who benefits most from dental procedures has more severe oral pathology.

REVIEWER

\- Line 223: Previous studies have also shown that pdC1INH prophylaxis is less effective for AAE-C1INH as compared to HAE-C1INH (reviewed for example in Cicardi et al, 2014). This observation is coherent with the increased C1INH catabolism characteristic of AAE-C1INH patients and may be influenced by the presence or absence of anti-C1INH autoantibodies in the patient, as suggested by the authors' data.

However, most experts recommend antifibrinolytic agents for the prophylaxis of AAE-C1INH; why were the two AAE-C1INH patients receiving pdC1INH instead? The reason of this treatment choice should be clear in the manuscript.

AUTHORS

We thank the Reviewer for this comment. There is no evidence from randomized clinical trials that antifibrinolytic agents are effective for STP in AAE-C1INH. These agents are contraindicated in some categories of patient, such as those receiving antiplatelet or anticoagulant therapy and those with procoagulant condition. This was the case of our patients and the reason why we chose pdC1INH for STP.

We clarified the reason of the treatment choice in the manuscript in the Discussion section.
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Reviewer \#2: All comments have been addressed

Reviewer \#3: (No Response)
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2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.
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Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?
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